Relapsed/Refractory CLL Updates From Atlanta - prIME Oncology
Clinical Spotlight
Clinical Spotlight

Relapsed/Refractory CLL Updates From Atlanta

Updates from the 2017 Annual Hematology Meeting

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Get expert insight on the most important chronic lymphocytic leukemia (CLL) data presented at the 2017 Annual Hematology Meeting in Atlanta. Drs Gribben and Seymour will highlight the latest trial data and its impact on clinical practice.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides





Release Date

Release Date

Dec 15, 2017

Expiration Date

Dec 15, 2018

Abstract #LBA-2: Venetoclax Plus Rituximab is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia – Results from the Pre-planned Interim Analysis of the Randomized Phase 3 Murano Study

Abstract #428: Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Abstract #432: Acalabrutinib With Obinutuzumab in Relapsed/Refractory and Treatment-Naïve Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study

Featured Experts

  • John Gribben, MD, DSc, FRCP, FRCPath, FMedSciBarts Cancer Institute
    London, United Kingdom
  • John Seymour, MBBS, PhD, FRACPPeter MacCallum Cancer Centre
    Melbourne, Victoria, Australia

After successful completion of this educational activity, participants should be able to:

  • Evaluate current treatment approaches for patients with relapsed/refractory CLL
  • Describe recent efficacy and safety findings for combinations incorporating targeted therapy and how these findings might impact clinical practice

This educational activity is supported by a grant from AbbVie.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This enduring activity is provided by prIME Oncology.

Disclosure Information


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.